NEJM: Artificial pancreatic system for the treatment of children with type 1 diabetes.

Researchers recently examined the effects of the artificial pancreatic closed-loop insulin administration system on blood sugar in children with type 1 diabetes.
The study was a 16-week multi-center, randomized, open-label, parallel trial involving children with type I diabetes between the ages of 6 and 13 who were randomly treated with artificial pancreatic insulin delivery closed-loop systems (closed-loop groups) or sensor-enhanced insulin pumps (control groups).
result of the study was the percentage of time glucose levels in the target range of 70 to 180 milligrams per minute.
101 children participated in the study, including 78 in the closed-loop group and 23 in the control group, with baseline glycation hemoglobin levels between 5.7% and 10.1%.
In the closed-loop group, the percentage of time when blood sugar levels remained in the target range of 70 to 180 mg/dL increased from 53 per cent at the baseline to 67 per cent, while in the control group it increased from 51 per cent to 55 per cent (an average difference of 11 per cent).
two groups, the percentage of time spent with blood sugar levels below 70 mg per d litre was lower, with a closed-loop group of 1.6 percent and a control group of 1.8 percent.
closed-loop group, the median percentage of time the system is in closed-loop mode is 93%.
group did not have diabetic ketoacidosis or severe hypoglycemia.
for children with type 1 diabetes, blood sugar maintenance was better than using sensor-enhanced insulin pumps with artificial pancreatic closed-loop systems.
.